DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nimotuzumab
Nimotuzumab
Nimotuzumab, an Antitumor Antibody That Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding While Permitting the Active Receptor Conformation
Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
KSMO 2021 CV SS Hye
Advances in Epidermal Growth Factor Receptor Specific Immunotherapy: Lessons to Be Learned from Armed Antibodies
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Nimotuzumab Inhibits Cholangiocarcinoma Cell
One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
The Two Tontti Tudiul Lui Hi Ha Unit
Development and Preclinical Evaluation of Cixutumumab Drug
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
Strategies to Overcome Bypass Mechanisms Mediating Clinical
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Radiotherapy Plus Nimotuzumab Or Placebo in The
Dual Targeting of the Epidermal Growth Factor Receptor Using
A Phase I, Pharmacokinetic and Pharmacodynamic Study of Nimotuzumab in Japanese Patients with Advanced Solid Tumors
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
Top View
Orphan Drug Designations and Approvals List As of 06‐02‐2014 Governs July 1, 2014 ‐ September 30, 2014
(INN) for Biological and Biotechnological Substances
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Nimotuzumab, Effective Immunotherapy for the Treatment Of
(QDB) Method for Prognosis of Gastric Cancer Patient
Drugs with Special Ordering Procedures (SAP Chart)
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
89Zr-Labeled Domain II-Specific Scfv-Fc Immunopet Probe
Letters to the Editor
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Antitumor Activity of Nimotuzumab in Combination with Cisplatin in Lung Cancer Cell Line A549 in Vitro
Therapeutic Potential of Nimotuzumab Pegylated-Maytansine Antibody Drug Conjugates Against EGFR Positive Xenograft
Com(2010)0397
Novel Systemic Therapies for Advanced Gastric Cancer
Nimotuzumab for Advanced Pancreatic Cancer – Second Line
Qualifying Therapeutic Discovery Project Grants
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
Receptor Tyrosine Kinases (Rtks) in Breast Cancer
A Randomized, Phase II Study of Gefitinib Alone Versus Nimotuzumab
Nimotuzumab in Advanced Cervical Cancer
Theraloc, INN: Nimotuzumab WITHDRAWAL
Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
Orphan Drug Designations and Approvals List As of 12‐01‐2014
Advances in Targeted Therapy for Esophageal Cancer
Roswell Park Cancer Institute
(INN) for Biological and Biotechnological Substances
Therapies Based on Inhibitors of the Epidermal Growth
Working Minutes of the Ephmra Classification Committee
Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
Nimotuzumab Site-Specifically Labeled with 89Zr and 225Ac Using
EGFR-Targeting As a Biological Therapy: Understanding Nimotuzumab’S Clinical Effects
(EGFR) Antibodies in Squamous Cell Carcinoma of the Head and Neck
Targeted Therapy in Esophageal Cancer
Assessment of the Evolution of Cancer Treatment Therapies
Mediated Docetaxel Efflux by Tyrosine Kinase Inhibitors in Human
111In and 225Ac-Labeled Cixutumumab for Imaging and Alpha
U.S. FDA Approves Mylan and Biocon's Ogivri™ the First
Innovación En Ca Gástrico 2ª Línea De Tratamiento
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
Nimotuzumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: a Retrospective Analysis
Sr. No Name of the Firm Name of the Drug Date of Permission Indication
Antibody Therapies in Cancer
Interne Voorbladen
The Relative Efficacy and Safety of Targeted Agents Used In